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Abstract
Background: We and others have shown that subtype C HIV-1 isolates from patients failing on a regimen containing
stavudine (d4T) or zidovudine (AZT) exhibit thymidine-associated mutations (TAMs) and K65R which can impair the efficacy
of Tenofovir (TDF) at second line. Depending on the various studies, the prevalence of K65R substitution as determined by
the Sanger method ranges from 4 to 30%. Our aim was to determine whether ultra-deep pyrosequencing (UDPS) could
provide more information than the Sanger method about selection of K65R in this population of patients.
Methods: 27 subtype C HIV-1 isolates from treated patients failing on a regimen with d4T or AZT plus lamivudine (3TC) plus
nevirapine (NVP) or efavirenz (EFV) and who had been sequenced by Sanger were investigated by UDPS at codon 65 of the
reverse transcriptase (RT). 18 isolates from naı ¨ve patients and dilutions of a control K65R plasmid were analysed by Sanger
plus UDPS.
Results: Analysis of Sanger sequences of subtype C HIV-1 isolates from naı ¨ve patients exhibited expected polymorphic
substitutions compared to subtype B but no drug resistance mutations (DRMs). Quantitation of K65R variants by UDPS
ranged from ,0.4% to 3.08%. Sanger sequences of viral isolates from patients at failure of d4T or AZT plus 3TC plus NVP or
EFV showed numerous DRMs to nucleoside reverse transcriptase inhibitors (NRTIs) including M184V, thymidine-associated
mutations (TAMs) plus DRMs to non- nucleoside reverse transcriptase inhibitors (NNRTIs). Two K65R were observed by
Sanger in this series of 27 samples with UDPS percentages of 27 and 87%. Other samples without K65R by Sanger exhibited
quantities of K65R variants ranging from ,0.4% to 0.80%, which were below the values observed in isolates from naı ¨ve
patients.
Conclusions: While Sanger sequencing of subtype C isolates from treated patients at failure of d4T or AZT plus 3TC plus
NVP or EFV exhibited numerous mutations including TAMs and 8% K65R, UDPS quantitation of K65R variants in the same
series did not provide any more information than Sanger.
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Introduction
We and others [1–2] have shown that subtype C HIV-1 isolates
from Indian patients who fail on first-line HAART composed of
stavudine (d4T) or zidovudine (AZT) plus lamivudine (3TC) plus
nevirapine (NVP) or efavirenz (EFV) and according to WHO
clinical and/or immunological criteria exhibit numerous drug
resistance mutations (DRMs) to nucleoside reverse transcriptase
inhibitors (NRTIs) and to non-nucleoside reverse transcriptase
inhibitors (NNRTIs) in the reverse transcriptase (RT) part of the
viral genome, including thymidine-associated mutations (TAMs)
and K65R (the prevalence of which was around 8% in our series).
When the RT sequences were introduced into the ANRS and
Stanford algorithms, both algorithms showed that the DRMs of
the first line induce a decreased susceptibility to tenofovir (TDF),
an NRTI drug that is still used as second line in some southern
countries. This has implications for public health because patients
who fail with a first-line regimen including d4T or AZT plus 3TC
plus NVP or EFV and who switch to 3TC plus TDF plus
ritonavir-boosted lopinavir (LPV/RTV) will in fact not be fully
susceptible to TDF and therefore to the second-line regimen.
TAMs and K65R are known to induce partial or full resistance to
TDF [3]. Regarding K65R, similar studies carried out in the same
context of failure on a first-line regimen including d4T, AZT or
dideoxyinosine (ddI) showed a prevalence of 4% in a South
African population where subtype C was predominant [4], 10.9%
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isolates from South Africa [6], 24% in Malawi with subtype C
viruses [7] and up to 30% in Botswana [8].
From a molecular point of view, it has been demonstrated that
the RT KKK nucleotide motif at codons 64, 65, 66 in reverse
transcriptase of subtype C HIV-1 appears to lead to template
pausing that facilitates the selection of K65R, even in isolates from
untreated patients [9–12]. Moreover, it has also been shown that
the KKK motif in this subtype can lead to PCR-induced K65R
[13].
The aim of the present study was to clarify the prevalence of
K65R in these subtype C isolates from patients failing on a first
line including d4T or AZT. Since we had the prevalence of K65R
by the Sanger sequencing method, we investigated K65R variants
by ultradeep pyrosequencing (UDPS) in the same samples as those
Table 1. Primers used for GS Junior ultradeep sequencing of
RT.
sequence 59-39 HXB2 position
RT PCR GS
Junior
primer 59 AGTAGGACCTACACCTGTCA 2480 to 2499
primer 39 CTGTTAGTGCTTTGGTTCCTCT 3399 to 3420
Nested GS
Junior
primer 59 GGCCATTGACAGAAGAAAAAATAAAAGC 2620 to 2647
primer 39 GGGATGTGGTATTCCTAATTGAACTTCC 2813 to 2840
doi:10.1371/journal.pone.0036549.t001
Table 2. RT polymorphic substitutions (Sanger) compared to reference HIV-1 B in isolates from naı ¨ve patients and amounts of
K65R and K70R mutations in the same isolates plus control plasmids.
naive patients RT sequence by Sanger method K65R K70R
1031 35Q, 39D, 48T, 48S, 60I, 73K, 73I, 122K, 135R, 162N, 173A, 174K, 177E, 178L, 200A,
207E, 211K, 214F, 245Q
,0.4% ,0.4%
1050 21I, 35T, 39E, 43K, 43R, 48T, 60I, 90I, 90V, 106M, 121Y, 135T, 135I, 158A, 158S, 162A, 162G,
170P, 170L, 173A, 177E, 179D, 200A, 207E, 211K, 214F, 221H, 221Y, 245Q
0,44% ,0.4%
1059 13R, 16N, 21G, 35T, 39D, 43R, 48T, 60I, 82R, 102Q, 107T, 107I, 121Y, 142I, 142V, 162A, 173A,
177E, 177D, 179I, 179V, 196E, 196G, 200A, 202V, 207G, 211K, 214F, 245Q, 250E
0,56% ,0.4%
1071 13K, 13R, 35T, 36A, 39E, 48T, 60I, 77I, 77F, 123E, 142V, 166R, 173A, 177E, 195L, 200A, 202V,
207A, 211K, 214F, 245Q
0,42% ,0.4%
1102 35T, 39N, 48T, 60I, 121H, 121Y,135R, 162A, 173A, 174K, 177E,200A, 207E, 211K, 214F, 245Q 0,71% ,0.4%
1113 20R, 35T, 36E, 36A, 39D, 60I,103K, 103N, 106M, 106V, 118I,121D, 121Y, 135T, 139S, 162A,
165V, 173T, 177E, 179D, 179V, 200A, 207E, 211K, 245Q
1,22% ,0.4%
1114 28K, 32E, 35T, 36A, 39D, 48T, 60I, 121H, 173A, 174Q, 174R, 177E, 178L, 190R, 194H, 200A,
207E, 214C, 225L
,0.4% ,0.4%
1116 20R, 35T, 39E, 48T, 60I, 102K, 102Q, 121Y, 135T, 138A, 162C, 173A, 200A, 207E, 207A, 211K,
214L, 214F, 245Q
1,18% ,0.4%
1117 35T, 36E, 36A, 39D, 48T, 60I, 64R, 121Y, 121C, 166R, 173T, 173A, 175N, 175H, 177E, 200A,
207K, 214F, 245Q, 250E
0,35% ,0.4%
1121 35T, 39E, 48T, 60I, 110H, 110D,121Y, 135R, 173T, 177E, 200A,207E, 214F, 217P, 217S,
245Q,248R, 249R, 251V, 252G, 254F, 255K
1,33% ,0.4%
1123 10I, 35T, 36A, 39D, 48T, 60I, 121H, 139T, 139S, 173S, 174K, 177E, 178I, 178V, 200A,
207A, 211K, 214F, 245Q, 252C
,0.4% ,0.4%
1125 13N, 35T, 39D, 43R, 48T, 60I, 121H, 121Y, 135T, 162A, 173A, 174R, 177E, 200A, 207E,
211K, 214F, 245Q
0,85% ,0.4%
1129 35T, 36A, 39D, 48T, 60I, 122K,139A, 173T, 177E, 178M, 200A, 207E, 211K, 214F, 245Q 0,75% ,0.4%
1131 36A, 39E, 48T, 55T, 55P, 73K,73I, 123S, 138E, 138V, 173A,177E, 200A, 207E, 211K,
214F, 245Q
3,08% ,0.4%
1132 35T, 36A, 39D, 48T, 60I, 122P,162C, 166R, 173T, 173A, 177E,200A, 202I, 202V, 207E, 211K,
214F, 245Q
1,02% ,0.4%
1133 35T, 36A, 39D, 48T, 60I, 122P,123E, 161Q, 161L, 166R, 173A,177E, 200A, 207E, 211K,
214F, 220K, 220I, 245E, 248K
,0.4% ,0.4%
1135 35T, 36A, 39D, 48T, 49K, 49R,60I, 121C, 159I, 159V, 160C,160F, 162S, 162C, 165I, 173T,
173A, 177E, 178M, 178L, 200A, 207E, 214F, 245Q
,0.4% ,0.4%
1139 35T, 39N, 48T, 60I, 102R, 104R, 121Y, 162A, 173A, 200A, 207K, 211K, 214F, 245Q ,0.4% ,0.4%
plasmid K65R 10% 94% ,0.4%
plasmid K65R 5% 2,30% ,0.4%
plasmid K65R 1% 0,90% ,0.4%
Footnote to Table 2. Two subtype C MJ4 plasmids, one with K65K (wild type) and one with K65R were used to amplify RT region before sequencing by UDPS.
Amplicon pools were not prepared in equimolar concentrations but with different percentages of K65R mutation. The theoretical and observed values of K65R plasmid
dilutions were 100%:94%, 5%:2.30% and 1%:0.90%.
doi:10.1371/journal.pone.0036549.t002
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provided additional knowledge to the Sanger results.
Methods
Subtype C HIV-1 isolates from Indian patients failing
(according to WHO clinical and/or immunological criteria) on a
first-line treatment including d4T or AZT plus 3TC plus NVP or
EFV were sequenced on RT by the Sanger method, and the
sequences were recorded in the Los Alamos database (GenBank
JF895621–JF895673). Among these samples, 27 were randomly
selected for investigation by UDPS using the Roche GS Junior
equipment. RNA extracted previously from the samples was used
to amplify a short region of RT with primers including specific
sequences for the GS Junior system (Table 1). The reverse
transcription used SuperScriptIII RTPCR enzyme (Invitrogen,
Carlsbad, CA) with 10 ul RNA, one cDNA synthesis cycle at 50uC
for 30 min and 40 cycles of PCR amplification. The nested PCR
used FastStart HiFi (Roche) with 2 ul of RTPCR product, 40
cycles of PCR amplification. Amplicons were purified by AMPure
kit (Agencourt Biosciences), quantified using Quant-iT Picogreen
(Invitrogen) and pooled at equimolar concentrations. Clonal
amplification on beads (EmPCR) was performed using the 454
Life Science reagents that enable bidirectional sequencing,
composed of a 30 cycle PCR amplification. DNA containing
beads were recovered and UDPS was performed on the GS Junior
sequencer (454 Life Sciences). Most of the samples had HIV viral
loads .100,000 copies/mL (mean: 379,753 copies/mL; IQR:
11209–5,817,977 copies/mL) and at least 1,000 clonal sequencing
reads were used for the analysis, allowing a 0.4% accuracy in the
quantitation [14]. Positions studied were codon 65 and codon 70,
which was chosen as a TAM position in NRTI-treated patients
leading to K70R, because it has been frequently observed in the
studied isolates and because 70R is considered to be a DRM and
not at all a substitution potentially related to polymorphism.
Since the viral isolates obtained at initiation of first-line therapy
were not available, the data obtained by Sanger and UDPS in
isolates from patients at failure were compared to those of subtype
C isolates from 18 naı ¨ve patients. Some of their bulk sequences
have been previously published by our group [15]. All codons
were analysed by Sanger while potential polymorphism at codons
65 and 70 was investigated by both Sanger and UDPS. As a
control, we used two subtype C MJ4 plasmids, one wild type and
one bearing K65R (both provided by Mark Wainberg’s group in
Montreal). The UDPS results of the study are available in
GenBank under accession number SRA 050640.
Results
Table 2 shows the Sanger results of viral isolates from naı ¨ve
patients and UDPS results of codons 65 plus 70 in these isolates,
together with UDPS results of control plasmids for codons 65 and
70. Analysis of Sanger results for naı ¨ve patients showed an
extensive polymorphism compared to subtype B without involve-
ment of substitutions 65R and 70R. K70R was ,0.4% by UDPS
in all isolates from naı ¨ve patients. K65R ranged from ,0.4% to
3.08% (mean 0.6660.76 standard deviation, SD).
Regarding the 27 isolates from treated patients at failure, the
drug resistance mutations (DRMs) according to the French ANRS
algorithm and following bulk DNA sequencing (Sanger) are listed
in Table 3. Most of them exhibited the M184V mutations to 3TC
of the regimen plus TAMs to d4T and/or AZT and DRMs to
NNRTIs. Only two samples (455 and 493) bore a K65R mutation,
one (455) cumulating K65R and the Q151M nucleoside analog
mutation (NAM). Table 4 compares the Sanger and UDPS data of
these isolates at codons 65 and 70. Quantitation of K65R by
UDPS ranged from ,0.4% to 87%. In the two isolates with K65R
by Sanger, percentages of K65R by UDPS were 27% and 87%. If
we only consider positions 65 found not to have K65R with
Sanger (25 samples), the quantities of K65R ranged from ,0.4%
to 0.80% (0.16260.22 SD). K70R with UDPS ranged from
,0.4% to 100%. Eight samples exhibited K70R with Sanger and
the corresponding UDPS values ranged from 34.50 to 100%.
Regarding positions 70 found not to have the K70R mutation with
Sanger (19), all of them were ,0.4% for 70R by UDPS except two
samples (470 and 489 with values of 1.80 and 4.40% respectively).
Table 3. RT bulk sequences of 27 subtype C HIV-1 isolates failing on first line.
patient RT sequence by Sanger method patient RT sequence by Sanger method
454 115F, 151M, 184V, 219Q, 90I, 181C, 221Y 479 41L, 44D, 67N, 75M, 184V, 215Y, 98G, 101E, 179I, 181C, 190A,
221Y
455 41L, 65R, 151M, 184V, 181V, 190A 480 41L, 67N, 69D, 70R, 184V, 210W, 215Y, 98G, 106M, 179I, 181C,
190A
456 67N, 70R, 184V, 215F, 219E, 98S, 181C 481 41L, 67N, 69insert, 75M, 184I, 210W, 215Y, 90I, 103N
461 41L, 44D, 69D, 184V, 90I, 179I, 181C 482 41L, 67N, 69D, 184V, 215Y, 101E, 179I, 188L, 190A
463 41L, 67N, 69D, 70R, 184V, 215Y, 188L, 221Y 485 no resistance mutation
464 184V, 98G, 101E, 181C, 190A 486 41L, 67N, 74V, 184V, 215Y, 101E, 138Q, 190S
465 41L,44D, 67N, 74V, 184V, 210W, 215Y, 101E, 179T, 181C, 190A 487 67N, 69D, 70R, 184V, 219Q, 98G, 179I, 190A
466 41L, 67N, 69D, 69N, 75M, 184V, 210W, 215Y, 101E, 179I, 190A 488 41L, 184V, 215Y, 103N, 225H
469 41L, 67N, 69N, 70R, 184V, 215F, 219E, 103N, 190A 489 74V, 184V, 215Y, 101E, 179I, 190C
470 no resistance mutation 493 65R, 75A, 219E, 179T, 181C, 190A, 221Y
471 41L, 184V, 215Y, 98G, 101E, 190A 495 41L, 184V, 210W, 215F, 90I, 103N
472 41L, 67N, 70R, 184V, 215Y, 219E, 181C 496 41L, 67N, 70R, 75M, 184V, 215F, 219Q, 106M, 190A
473 41L, 44D, 67N, 70R, 75M, 184V, 215Y, 103N, 190A 501 41L, 67N, 75M, 184V, 210W, 215Y, 101E, 190S
475 41L, 67N, 69D, 75M, 184V, 215Y, 101E, 179I, 188L, 190A
DRMs are noted according to ANRS.
doi:10.1371/journal.pone.0036549.t003
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Sanger and UDPS results in isolates from naı ¨ve patients
Although UDPS has limitations particularly with regard to
polymerization and pyrosequencing errors [13,16], recent studies
with different methods (UDPS, allele specific PCR) have shown
that K65R is identified more frequently in subtype C HIV-1 from
naı ¨ve patients [14,17]. In our naı ¨ve patients, there was a clear
difference between K70R (mean 0%) and K65R (mean 0.66%)
(Table 2). Our data on position 65 are in agreement with those of
Kozal et al [14], ranging from ,0.4% to 1.33% apart from one
sample (1131) at 3.08%. We were not expecting selection of K65R
in this population of patients who were quite distant from primary
infection and therefore from potential transmission of K65R
mutants. For us, this naı ¨ve population was the basis of an
evaluation of natural variation at codon 65 in subtype C HIV-1.
Sanger and UDPS results of isolates from treated patients
at failure
The Sanger results of isolates from treated patients were as
expected with a predominance of M184V, numerous TAMs of
pathway1 (M41L, D67N, K70R, L210W, T215Y/F) and DRMs
to NNRTIs (mainly K101E, K103N, V106M, Y181C, G190A).
As mentioned above, 2 isolates of the series exhibited a K65R
substitution.
With regard to UDPS results at codon 70, the quantitative data
were different from those recorded in naı ¨ve patients: 8 isolates
exhibiting K70R with Sanger had UDPS K70R values above
34.60%, while 2 samples without K70R with Sanger (470 and 489)
had K70R variants at quantities above the ,0.4% background
observed in naı ¨ve patients. We hypothesize that these isolates are
undergoing a process of selecting K70R mutations. Regarding the
K65R values apart the two samples with K65R by Sanger, the
UDPS quantities of K65R variants were low and below those of
isolates from naı ¨ve patients. Our results are not in accordance with
those obtained by another group [18] using an allele- specific PCR
which exhibited minority variants of K65R in four subtype C
HIV-1 isolates out of 30 patients having received NRTIs at first
line; it must be pointed out that this technique uses an intercalating
dye and high-melt resolution assay which can be difficult to
interpret due to genomic variability in the flanking region of codon
65.
K65R substitutions are generated in subtype C isolates from
naı ¨ve patients due to the 64–65–66 motif. There are some
constraints in experienced patients failing on a suboptimal regimen
with d4T or AZT plus 3TC plus NVP or EFV. We first
hypothesize that 184V, which was the most prevalent mutation
observed in our series of treated patients at failure, has dampened
the emergence of 65R as noted by others [3]. Second, there is an
antagonism between TAMs and K65R, while the latter can be
found in association with NAMs (Q151M) and is considered to be
increasingly selected in the presence of DRMs to NNRTIs and
particularly Y181C and G190A. As noted above, the prevalence of
K65R in this clinical context of failure ranges from 4 to 30%. In
our series, we estimate this prevalence to be 8% and the UDPS
data did not reveal any process of K65R selection that cannot be
assessed by Sanger sequencing.
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